International Comparison of Qualification Process for Medical Product Development Tools

Author:

Uchijima DaichiORCID,Kano Shingo

Abstract

Abstract Introduction Qualification of medical product evaluation tools is underway in the United States, Europe, and Japan to reflect the advancements in the basic science of medical products. In Europe and the U.S., Guidance of Guidances (GoG) policies that clarify regulators’processes, tasks, and methods of sponsor involvement are adopted to issue tool guidance. However, in Japan, a non-GoG type policy focusing on supporting the research and development for tools without defining a tool guidance-making process has been adopted. Methods In this study, an analytical framework for the lifecycle of development tools was constructed, including pre- and post-tool qualification processes, to compare the two above-mentioned approaches. For this study, Japanese cases were selected as experimental cases, whereas Western cases served as controls. The progress of tool qualification and composition of deliverables were analyzed. Results and Conclusions It was indicated that in the GoG type policy, in which processes are defined, and involvement methods are clarified, tool qualification can progress more smoothly than in a non-GoG type policy. This policy indicates that deliverables may have a consistent composition. Contrastingly, GoG-type policies alone present challenges in connecting upstream tools for R&D support.

Funder

Research Institute of Science and Technology for Society

The University of Tokyo

Publisher

Springer Science and Business Media LLC

Reference55 articles.

1. Critical Path Initiative information page (website) (https://www.fda.gov/science-research/science-and-research-special-topics/critical-path-initiative)

2. Innovation / Stagnation: challenge and opportunity on the critical path to new medical products (FDA’s report) (https://c-path.org/wp-content/uploads/2013/08/FDACPIReport.pdf)

3. Goodsaid F, Papaluca M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol. 2010;28:441–3.

4. Walker EG, Brumfield M, Compton C, et al. Evolving global regulatory science through the voluntary submission of data: a 2013 assessment. Ther Innov Regul Sci. 2014;48:236–45.

5. Woodcock J, Buckman S, Goodsaid F, et al. Qualifying biomarkers for use in drug development: a US food and drug administration overview. Expert Opin Med Diagn. 2011;24:369–74.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3